Linkage analyses have implicated chromosome 7p21.3 as a susceptibility region for inflammatory bowel disease (IBD). Recently, the mouse phenotype with diarrhea and goblet cell dysfunction caused by anterior gradient protein 2 dysfunction was reported (European patent WO2004056858). The genes encoding for the human homologues AGR2 and AGR3 are localized on chromosome 7p21.3. The gene structures were verified and mutation detection was performed in 47 IBD patients. A total of 30 single nucleotide polymorphisms (SNPs) were tested for association to ulcerative colitis (UC, N ¼ 317) and Crohn's disease (CD, N ¼ 631) in a German cohort and verified in a UK cohort of 384 CD and 311 UC patients. An association signal was identified in the 5 0 region of the AGR2 gene (most significant SNP hcv1702494, nominal P TDT ¼ 0.011, P case/control ¼ 0.0007, OR ¼ 1.34, combined cohort). The risk haplotype carried an odds ratio of 1.43 in the German population (P ¼ 0.002). AGR2 was downregulated in UC patients as compared to normal controls (Po0.001) and a trend toward lower expression was seen in carriers of the risk alleles. Luciferase assays of the AGR2 promoter showed regulation by the goblet cell-specific transcription factors FOXA1 and FOXA2. In summary, AGR2 represents an interesting new avenue into the etiopathophysiology of IBD and the maintenance of epithelial integrity.
Introduction
Inflammatory bowel disease (IBD) refers to a group of complex chronically relapsing autoimmune disorders of the gastrointestinal tract. It affects 0.1-0.5% individuals in Western countries, with the median onset age in early adulthood. 1, 2 On the basis of clinical and histopathological features, IBD is categorized into two main disease entities: Crohn's disease (CD) and ulcerative colitis (UC). 3, 4 Active inflammation is marked by chronic diarrhea, rectal bleeding, abdominal pain, fever, weight loss and extraintestinal manifestations, for example, arthritis, uveitis and skin lesions. IBD is a multifactorial disease caused by the interplay of genetic, environmental and immunological factors. 5, 6 Epidemiological studies have consistently shown a familial clustering of IBD [7] [8] [9] as well as an increased concordance among monozygotic twins. 10, 11 Genetic linkage studies in IBD provide a thorough proof for a genetic background, 12 and the first disease gene (NOD2 or CARD15) has been identified for CD. [13] [14] [15] [16] [17] Genome-wide linkage analyses in large patient cohorts of different ethnic backgrounds have defined IBD susceptibility loci located on chromosomes 3, 6, 7, 12 and 16. 12, [18] [19] [20] Recently, mutations in the murine Anterior Gradient 2 (AGR2) gene have been associated with a spontaneous phenotype characterized by diarrhea and goblet cell dysfunction resembling pathological changes seen in human UC (European patent WO2004056858). Two closely related human homologues (human AGR2 and AGR3 genes) of the mouse gene are located on chromosome 7p21.3, a location supported by the sequence of the human genome assembly (NCBI build 35), earlier radiation hybrid mapping and fluorescence in situ hybridization. 21 This chromosomal region has been implicated as a susceptibility region for IBD in a previous genome-wide linkage analysis with stronger evidence for linkage in the UC group. 18 Expression of AGR2 has been reported in mucus-secreting cells and endocrine organs. 22 Thus, we selected the human AGR2 and AGR3 (BCMP11) genes as functional and positional candidate genes for IBD for an in-depth investigation.
Subjects and methods

Investigated patient sample
In this study, two groups of participants were investigated. The first group included a sample of 383 cases from families and 565 trios with IBD (631 with CD, 317 with UC) and 537 unrelated healthy control individuals of German extraction. The second group consisted of 604 cases from families and 91 trios (384 with CD and 311 with UC) and 360 unrelated healthy control individuals from the United Kingdom. For each affected individual, the diagnosis of either CD or UC was confirmed by standard diagnostic criteria. 3, 23 Ascertainment criteria were determined before the initiation of patient collection. German patients and their family members were recruited at the 1st Department of Medicine at the Hospital Schleswig-Holstein, Campus Kiel (Kiel, Germany), the Charité University Hospital (Berlin, Germany) and other collection centers in Germany. The control individuals were collected through the Department of Transfusion Medicine at the University Hospital Schleswig-Holstein and through the POPGEN population project (www.popgen.de). UK families were sampled through the King's College School of Medicine, Guy's Hospital, and the St Mark's Hospital London (UK). The cohorts have been used in a number of previous studies and the clinical and ethical issues of the recruitment process were reviewed as part of these publications. 19, 16, 24, 15 An overview of the investigated sample is given in Table 1 .
cDNA cloning
The public databases and the Celera Discovery Systems were reviewed in order to establish gene models for the AGR2 and AGR3 genes. For AGR2, two additional 5 0 exons were annotated. The presence of the additional 5 0 exons was investigated through RT-PCR in the Clontech multiple tissue panels I and II (East Meadow Circle, Palo Alto, USA), using standard supplier's protocols. For the gene structure evaluation of AGR2, the following primers were used: (1) for the short form: AGRf5: TCA ACT CTG GCC AGG AAC TC; AGRr5: TAC AGC ACC ATA GTC CAG GG and (2) for the long form: AGRf11: CGA CTC ACA CAA GGC AGG T; AGRr11: GCT GTA TCT GCA GGT TCG T -designed on the basis of the NCBI and Celera gene models.
Mutation detection and genotyping
A total of 21 pairs of primers were designed to cover all exons and the promoter region of the AGR2 and AGR3 genes. Amplification was performed with an ABI GeneAmp s PCR System 9700 (Applied Biosystems Inc., Foster City, CA, USA) using the following thermoprofile: 961C -10 min, (961C -1 min; 59-68.71C -1 min (À0.51C per step); 721C -1 min) 16 Â , (961C -1 min; 51.2-60.71C -1 min; 721C -1 min) 25 Â , 721C -10 min. The BigDye chemistry (ABI) was used according to the manufacturer's recommendations for the sequencing reactions and analyzed on ABI3700 and ABI3730 automated sequencers. Mutation detection was performed in a set of 47 unrelated German individuals affected with IBD (24 patients with CD, 23 patients with UC). Genotyping was performed on an automated platform using the ABI Taqman technology as described. 25, 26 Statistical analysis Family-based analyses were performed using the transmission disequilibrium test (TDT) 27 in trios, using TRANSMIT 28 and GENEHUNTER. 29 Haplotype frequency estimates among singletons were obtained using an implementation of the EM algorithm (HAPMAX). 30 Significance testing of haplotype frequency differences was also performed with HAPMAX, making use of the fact that twice the log-likelihood ratio between two nested data models approximately follows a w 2 distribution with k degrees of freedom, where k is the difference in parameter number between the two models. Significance assessment of associations with or between single locus genotypes was performed using w 2 or Fisher's exact test for 2 Â 3 contingency tables. All other statistical calculations were performed with SPSS. Throughout the manuscript, nominal P-values are given unless specified differently.
Cell culture and reporter gene constructs HEK 293 cells were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). The cells were cultured in DMEM þ 10% fetal calf serum. At 1 day before transfection, cells were seeded at a density of 5 Â 10 5 cells/2 ml on 6-well plates. Transfections were performed with Fugene 6 (Roche, Switzerland) according to the manufacturer's manual using 0.08 mg of the target plasmid and 0.02 mg of the pRL-TK reference plasmid (Promega, Mannheim, Germany) for the reporter gene assays. The constructs for the goblet cell transcription factors FOXA1 and FOXA2 have been described elsewhere (Rausa, FM 2003 MCB). At 24 h after transfection, the cells were harvested for reporter gene assay. Transfection efficiency was determined by parallel detection of pRL-TK activity in a dual luciferase reporter gene assay (Promega, Madison, WI, USA). Every single transfection experi- Non-overlapping categories are given. Single cases were randomly selected from IBD families.
AGR2 and AGR3 in IBD W Zheng et al ment was performed in duplicate and was repeated at least three times. The AGR2 promoter of the short form (NM_006408) from À1542 to À1 was amplified from 100 ng of human genomic DNA by PCR under standard conditions with the following primers (restriction sites underlined): pGL_AGR2_N_sense(XhoI): CGC TCG AGA TCT TTA CAG AGG TAA TTA AGT TAA AGT A; pGL_AGR2_N_anti(HindIII): GCA AGC TTG TTG CTA ACT CAG AAA CGA ACC TTC CTT TCC CCA A. It was then cloned into the pGL3-basic plasmid (Promega). All constructs were sequence-verified with an ABI3700 sequencer (ABI, Foster City, CA, USA) before use.
Dual luciferase reporter gene assay Luciferase activity was determined with a dual luciferase reporter gene kit (DLR) from Promega according to the manufacturer's manual. The cells lysates were analyzed with a MicroLumatPlus LB96V microplate luminometer (EG&G Berthold, Wellesley, MA, USA) after automatic injection of the necessary substrate solutions. All samples were measured at least in duplicate. The results for firefly luciferase activity were normalized to Renilla luciferase activity.
Real-time PCR
RNA transcript levels were measured using quantitative real-time PCR in 138 patient and normal control samples, including 25 normal controls, 56 CD and 57 UC patients. Biopsies were obtained from small and large bowel, with 125 of the 138 samples originating from the sigmoid colon. Patients included in this study consented to the additional research biopsies being taken 24 h before endoscopy. The study protocol was approved by the hospital ethical committee before the start of the study. Total RNA was isolated from snap-frozen biopsies using a commercial kit (Qiagen, Hilden, Germany 
Results
cDNA cloning
The gene model of AGR2 was evaluated using RT-PCR in a tissue panel designed on the basis of the NCBI and Celera gene models. The presence of the additional 5 0 exon predicted in the Celera database was confirmed.
The two different transcripts also show a significantly different expression pattern (Figure 1 ). The extended form shows a predominant expression in the prostate whereas the shorter form shows a ubiquitous expression pattern. The resultant gene model has been submitted to GenBank.
Mutation detection
The mutation detection experiment identified a total of 30 single nucleotide polymorphisms (SNPs), of which 19 were not previously known. A total of 25 SNPs are located in the AGR2 gene and five map to the AGR3 gene. One SNP (hcv111845 -rs4719482) would lead to an amino-acid exchange in the additional N-terminal sequence of the extended splice variant. An overview of all identified SNPs is given in Table 2 .
Association analysis
The German study cohort (Table 1 ) and 537 healthy controls of German descent were genotyped for 30 SNPs of the genes AGR2 and AGR3. All markers were in Hardy-Weinberg equilibrium both in the case and control sample. Case-control and TDT tests of association were performed for IBD and the subphenotypes CD and UC, separately. Results are shown in Table 3 .
Markers passing a nominal threshold of Po0.05 in the German screening sample were further investigated in an independent patient and control sample from the UK. Association statistics in the UK, German and combined cohorts for three diagnostic categories (UC, CD, IBD) are presented in Table 4a -c. Results that meet nominal P-value criterion of 0.05 are highlighted in bold.
The consistency of the TDT and case-control statistics and the strength of replication between populations were used as a pragmatic guide to judge the trustworthiness of the positional signals. The linkage disequilibrium (LD) structure of the human AGR2 and AGR3 gene regions is shown in Figure 2 using the r 2 measure of LD. Taking into account the LD data and the association results (Tables 3 and 4) , the association is most consistent in the UC phenotype and localizes to the 5 0 region of the AGR2 gene (Figure 2 ). The association is most pronounced at hcv1702494 (combined sample: P TDT ¼ 0. 
Expression analysis
The relative expression of total AGR2 was quantified by real-time PCR in 25 normal controls, 56 CD and 57 UC patients. Median expression levels (arbitrary normalization units) of 1.07 for normal controls, 0.57 for CD and 0.67 for UC were observed. This expression difference was statistically significant as tested by nonparametric testing (P ¼ 0.0000001 for CD versus NC and P ¼ 0.0000001 for UC versus NC; Mann-Whitney U-test; Figure 3 ). For 91 IBD biopsies, genotype data for the AGR markers was available. Individuals who were homozygous for the risk allele at marker hcv111845 showed an overall lower expression relative expression level than the remainder of the samples (relative expression level 0.63 for '22' genotype versus 0.71 for '11' and '12' ). However, this difference was not statistically significant owing to the limited sample number (P40.1). The power to detect this expression difference (0.08) at the P 0 p0.05 level in the sample was 48%. 
Discussion
The AGR2 gene is the human homologue of the Xenopus laevis cement gland gene XAG-1, mapping to chromosome band 7p21.3. 21 This gene is highly expressed in the trachea, lung stomach, colon, prostate and small intestine. 22 In X. laevis, the XAG family of genes are expressed in a gradient in the ectoderm during early development of the cement gland, and appear to be important factors during differentiation of this organ. 31 The cement gland arises from the outer layer of embryonic ectoderm and forms a cone of columnar epithelium. AGR2 has been found to be expressed in tissues that contain mucoussecreting cells and/or function as endocrine organs. Thus, from an evolutionary perspective, the human AGR genes may be involved in the epithelial barrier function.
The hypothesis of involvement of the AGR2 gene in epithelial barrier function is further supported by the regulation of the AGR2 promoter by transcription factors typical for epithelial goblet cells. Luciferase reporter gene assays show an activation of human AGR2 promoter by FOXA1 and FOXA2. FOXA1 contributes to pancreatic beta-cell function 32 and both regulate signaling and transcriptional programs required for morphogenesis and goblet cell differentiation during formation. 33, 34 There is a binding site for Hepatic Nuclear Factor 1 (HNF1) in the AGR2 promoter region at SNP 07AGRNP53. HNF1 and FOXA1 and FOXA2 belong to the same family.
The analyses throughout the manuscript present nominal P-values. Upon rigorous Bonferroni correction, only the marker hcv8302351 would remain significant in the German screening sample at the 0.05 level. If a conditional analysis was performed, using for instance the TDT results in the German population as a screening test with a Pp0.05 threshold, both hcv1702494 and hcv8302351 would pass this threshold. Overall, we observe association of markers in the 5 0 region of AGR2 primarily with the UC phenotype in two independent cohorts (UK and German extraction). All of those four significant SNPs are located in the 5 0 end of the AGR2 gene (Table 2 ) and 07AGRNP53 and 07AGRNP261, which are part of the risk haplotype, are located in the promoter region. The expression level of AGR2 in UC patients was significantly lower than in health controls. Also, a trend toward lower expression of AGR2 in carriers of the risk alleles was observed. The link between downregulation of the AGR2 transcript in risk allele carriers and in disease has not yet been fully explored. None of the individual promoter SNPs identified in this study (Table 2 ) fully defines the disease haplotype, and also the more distant markers hcv1702494 and hcv111845 are needed for the definition of the risk haplotype. This suggests that further, as yet unidentified, private mutations contribute to the downregulation of AGR2 in disease.
In summary, we demonstrate association of the 5 0 region of the AGR2 gene to the UC phenotype in two independent populations. Functionally, the gene may be involved in the maintenance of epithelial integrity based on the mouse model, phylogenetic background and activation by transcription factors, which are characteristic for epithelial goblet cells. The disease effect is likely to be mediated through downregulation of the AGR2 transcript in disease, as suggested by association to individual promoter SNPs. The mechanistic risk profile of the risk haplotype is functionally not yet fully explored and possibly includes further private mutations in more distant regulatory elements. The impact of the risk mutations on the overall phenotype is moderate as indicated by allelic odds ratios in the range of 1.3-1.4. Overall, the AGR2 represents an interesting new avenue into the etiopathophysiology of IBD and warrants further evaluation in additional, independent populations.
